• News
  • SAN DIEGO
  • Finance

Isis gains most in 5 years on analyst praise for novel drug

Isis Pharmaceuticals Inc. (Nasdaq: ISIS) rose the most in almost five years after Cowen & Co. analyst Eric Schmidt raised his rating to outperform from neutral based on an experimental therapy's likelihood of becoming a blockbuster.

Isis jumped 14 percent to $8.78 at the close of trading in New York, for its largest single-day gain since January 2008. Shares of the Carlsbad-based company have increased 22 percent this year.

Isis develops therapies with its antisense technology, which works by manipulating chemical compounds so they bind to and disable the action of some disease-linked genes. Drugmakers such as Sanofi, GlaxoSmithKline Plc (NYSE: GSK) and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) have been partners with Isis to bring therapies to market. The company is developing a treatment with Biogen Idec Inc. (Nasdaq: BIIB) for spinal muscular atrophy, called ISIS-SMNRx, that may reach sales of $1 billion plus, Schmidt wrote today in a note to clients.

"Our confidence in ISIS-SMNRx in particular is growing," Schmidt said. "We forecast approval of ISIS-SMNRx in 2016 and believe the drug has blockbuster potential."

While Isis has declined 50 percent since September because of "diminished expectations" for Kynamro, a drug being developed with Paris-based Sanofi to treat a hyper form of high cholesterol in people with a rare genetic disease, Schmidt said the company's pipeline is undervalued.

"Our enthusiasm for Isis's antisense platform and pipeline (20+ candidates in clinical development) continues to grow," he wrote.

U.S. regulators are scheduled to decide whether to approve Kynamro by January.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Isis Pharmaceuticals Inc.

Company Website

1896 Rutherford Road
Carlsbad, CA 92008

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ISIS
44.62
  0.68  
+ 1.55%
1,703,078,000
77.8
37.38

Insider Trade Data

Date Insider Shares Type Value
10/02/2015 Parshall, B Lynne 12,436 Sell $506,747
10/02/2015 Parshall, B Lynne 12,436 Exchange $151,720
10/02/2015 Parshall, B Lynne 12,436 Sell $506,747
10/02/2015 Parshall, B Lynne 12,436 Exchange $151,720
07/06/2015 Crooke, Stanley T 12,350 Sell $707,457

Isis Pharmaceuticals Inc. Executive(s):

Stanley Crooke

  • Chairman, Chief Executive Officer, Founder, President

Similar Companies

NAICS - 325414 - Biological Product (except Diagnostic) Manufacturing
Subscribe Today!